Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis

Arthritis Research and Therapy

Volumn 12, Issue 2, 2010, Pages

  Page, Charlotte E ^a   Smale, Shaun ^b   Carty, Sara M ^b   Amos, Nicholas ^a   Lauder, Sarah N ^b   Goodfellow, Rhian M ^b   Richards, Peter J ^c   Jones, Simon A ^c   Topley, Nicholas ^c   Williams, Anwen S ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE DEGENERATION; CLINICAL ARTICLE; DRUG MECHANISM; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN SECRETION; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SYNOVIUM; ANIMAL; ARTHRITIS; BAGG ALBINO MOUSE; CARTILAGE CELL; CATTLE; COCULTURE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MOUSE MUTANT; NEWBORN; PATHOLOGY;

AGED; ANIMALS; ANIMALS, NEWBORN; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; CATTLE; CHONDROCYTES; COCULTURE TECHNIQUES; FEMALE; FIBROBLASTS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MIDDLE AGED; SYNOVIAL MEMBRANE;

EID: 77956989792     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2960     Document Type: Article

References (47)

1. Ring GH, Dai Z, Saleem S, Baddoura FK, Lakkis FG. Increased susceptibility to immunologically mediated glomerulonephritis in IFN-gamma-deficient mice. J Immunol 1999, 163:2243-2248.
2. Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, Caspi RR. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997, 158:5997-6005.
3. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996, 156:5-7.
4. Eriksson U, Kurrer MO, Sebald W, Brombacher F, Kopf M. Dual role of the IL-12/IFN-gamma axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-gamma. J Immunol 2001, 167:5464-5469.
5. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507-5513.
6. Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, Huang S, Boissier MC, Fournier C. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997, 158:5501-5506.
7. Williams AS, Richards PJ, Thomas E, Carty S, Nowell MA, Goodfellow RM, Dent CM, Williams BD, Jones SA, Topley N. Interferon-gamma protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis Rheum 2007, 56:2244-2254. 10.1002/art.22732, 17599735.
8. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141. 10.1038/ni1261, 1618871, 16200068.
9. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005, 7:R784-795. 10.1186/ar1733, 1175027, 15987480.
10. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2006, 20:849-863. 10.1016/j.berh.2006.05.005, 16980210.
11. Firestein GS. Pathogenesis of rheumatoid arthritis: how early is early?. Arthritis Res Ther 2005, 7:157-159. 10.1186/ar1780, 1175047, 15987499.
12. Ikeda K, Cox S, Emery P. Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?. Arthritis Res Ther 2007, 9:211. 10.1186/ar2177, 2206357, 17540047.
13. Cunnane G, FitzGerald O, Beeton C, Cawston TE, Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 2001, 44:2263-2274. 10.1002/1529-0131(200110)44:10<2263::AID-ART389>3.0.CO;2-1, 11665967.
14. Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S, Bresnihan B. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001, 44:1744-1753. 10.1002/1529-0131(200108)44:8<1744::AID-ART309>3.0.CO;2-K, 11508424.
15. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, Kinne RW, Santavirta S, Sorsa T, Lopez-Otin C, Takagi M. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999, 58:691-697. 10.1136/ard.58.11.691, 1752794, 10531073.
16. Redman SN, Dowthwaite GP, Thomson BM, Archer CW. The cellular responses of articular cartilage to sharp and blunt trauma. Osteoarthritis Cartilage 2004, 12:106-116. 10.1016/j.joca.2002.12.001, 14723870.
17. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, Williams AS, Jones SA. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003, 171:3202-3209.
18. Grogan SP, Barbero A, Winkelmann V, Rieser F, Fitzsimmons JS, O'Driscoll S, Martin I, Mainil-Varlet P. Visual histological grading system for the evaluation of in vitro-generated neocartilage. Tissue Eng 2006, 12:2141-2149. 10.1089/ten.2006.12.2141, 16968155.
19. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007, 56:3236-3247. 10.1002/art.22923, 17907159.
20. Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 2000, 59(Suppl 1):i103-108. 10.1136/ard.59.suppl_1.i103, 1766616, 11053099.
21. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000, 59:455-461. 10.1136/ard.59.6.455, 1753174, 10834863.
22. Tsubaki T, Arita N, Kawakami T, Shiratsuchi T, Yamamoto H, Takubo N, Yamada K, Nakata S, Yamamoto S, Nose M. Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens. Arthritis Res Ther 2005, 7:R825-836. 10.1186/ar1751, 1175033, 15987484.
23. Konttinen YT, Bergroth V, Nordstrom D, Koota K, Skrifvars B, Hagman G, Friman C, Hamalainen M, Slatis P. Cellular immunohistopathology of acute, subacute, and chronic synovitis in rheumatoid arthritis. Ann Rheum Dis 1985, 44:549-555. 10.1136/ard.44.8.549, 1001700, 3875323.
24. Schumacher HR, Bautista BB, Krauser RE, Mathur AK, Gall EP. Histological appearance of the synovium in early rheumatoid arthritis. Semin Arthritis Rheum 1994, 23:3-10. 10.1016/0049-0172(94)90079-5, 7939728.
25. Berg WB, Joosten LA, van Lent PL. Murine antigen-induced arthritis. Methods Mol Med 2007, 136:243-253. full_text, 17983153.
26. Schurigt U, Stopfel N, Huckel M, Pfirschke C, Wiederanders B, Brauer R. Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis. Arthritis Res Ther 2005, 7:R174-R188. 10.1186/ar1466, 1064893, 15642138.
27. Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD. Fibroblasts as novel therapeutic targets in chronic inflammation. Br J Pharmacol 2008, 153(Suppl 1):S241-S246. 10.1038/sj.bjp.0707487, 2268075, 17965753.
28. Buckley CD, Filer A, Haworth O, Parsonage G, Salmon M. Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease. Ann Rheum Dis 2004, 63(Suppl 2):ii92-ii95. 10.1136/ard.2004.028332, 1766776, 15479882.
29. Andereya S, Streich N, Schmidt-Rohlfing B, Mumme T, Muller-Rath R, Schneider U. Comparison of modern marker proteins in serum and synovial fluid in patients with advanced osteoarthrosis and rheumatoid arthritis. Rheumatol Int 2006, 26:432-438. 10.1007/s00296-005-0006-2, 16001180.
30. Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N, Yamanaka H. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 2007, 17:403-408. 10.1007/s10165-007-0608-5, 17929133.
31. Ates A, Turkcapar N, Olmez U, Tiryaki O, Duzgun N, Uguz E, Duman M. Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers. Rheumatol Int 2007, 27:715-722. 10.1007/s00296-007-0338-1, 17426976.
32. Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006, 20:983-1002. 10.1016/j.berh.2006.06.007, 16980219.
33. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994, 37:1774-1783. 10.1002/art.1780371211, 7986224.
34. Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole AR. Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 2001, 44:2503-2511. 10.1002/1529-0131(200111)44:11<2503::AID-ART430>3.0.CO;2-P, 11710706.
35. Simon J, Surber R, Kleinstauber G, Petrow PK, Henzgen S, Kinne RW, Brauer R. Systemic macrophage activation in locally-induced experimental arthritis. J Autoimmun 2001, 17:127-136. 10.1006/jaut.2001.0534, 11591121.
36. Joronen K, Kahari VM, Vuorio E. Temporospatial expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in mouse antigen-induced arthritis. Histochem Cell Biol 2005, 124:535-545. 10.1007/s00418-005-0011-2, 16133125.
37. Schumacher HR, Kitridou RC. Synovitis of recent onset. A clinicopathologic study during the first month of disease. Arthritis Rheum 1972, 15:465-485. 10.1002/art.1780150502, 4117789.
38. Henrotin YE, Zheng SX, Labasse AH, Deby GP, Crielaard JM, Reginster JY. Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis Cartilage 2000, 8:474-482. 10.1053/joca.1999.0323, 11069732.
39. Andrews HJ, Bunning RA, Plumpton TA, Clark IM, Russell RG, Cawston TE. Inhibition of interleukin-1-induced collagenase production in human articular chondrocytes in vitro by recombinant human interferon-gamma. Arthritis Rheum 1990, 33:1733-1738. 10.1002/art.1780331119, 2173607.
40. Hu X, Ho HH, Lou O, Hidaka C, Ivashkiv LB. Homeostatic role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction. J Immunol 2005, 175:131-138.
41. Kelchtermans H, Struyf S, De Klerck B, Mitera T, Alen M, Geboes L, Van Balen M, Dillen C, Put W, Gysemans C, Billiau A, Van Damme J, Matthys P. Protective role of IFN-gamma in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. J Leukoc Biol 2007, 81:1044-1053. 10.1189/jlb.0806486, 17200147.
42. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005, 201:1925-1935. 10.1084/jem.20050419, 2212028, 15967822.
43. Feng G, Gao W, Strom TB, Oukka M, Francis RS, Wood KJ, Bushell A. Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol 2008, 38:2512-2527. 10.1002/eji.200838411, 18792404.
44. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682. 10.1084/jem.20061775, 2118166, 17088434.
45. Moller B, Paulukat J, Nold M, Behrens M, Kukoc-Zivojnov N, Kaltwasser JP, Pfeilschifter J, Muhl H. Interferon-gamma induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology (Oxford) 2003, 42:442-445. 10.1093/rheumatology/keg146, 12626794.
46. Veys EM, Menkes CJ, Emery P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997, 40:62-68. 10.1002/art.1780400110, 9008601.
47. Machold KP, Neumann K, Smolen JS. Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann Rheum Dis 1992, 51:1039-1043. 10.1136/ard.51.9.1039, 1004833, 1417133.